CClinicalTrials.gg
CompletedNCT03403933Updated May 9, 2023

Vitamin D Supplementation on in Major Orthopedic Surgery

A Phase 4 interventional study of Didrogyl in Hypovitaminosis D and Cardiovascular Diseases, sponsored by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio. Completed at 1 site in Italy. Open to participants aged 55 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
55 Years to 85 Years
Sex
All
01

Study summary

Prospective, monocentric study in open, aimed at evaluating the effects of supplementation with calcifediol on left ventricular function parameters in cardiopathic subjects undergoing major orthopedic surgery.

Read the detailed description

Population of the study: 47 cardiopathic patients with hypovitaminosis D supplemented with calcifediol to reach vitamin D levels> 30 ng / ml within 6 months. The purpose of this study is to evaluate the improvement of the ejection fraction or GLS (global longitudinal strain) calculated by speckle tracking at 6 months in cardiopathic patients with vitamin D deficiency during functional recovery after major orthopedic surgery.

02

Conditions studied

  • Hypovitaminosis D
  • Cardiovascular Diseases
03

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age: > or equal to 55 years, \< or equal to 85 years
  • cardiopathic patients (including hypertension) who must undergo major orthopedic surgery at our site
  • patients with diagnosis: hypovitaminosis d

Exclusion criteria

Exclusion Criteria:

  • presence of neoplasm
  • endocrinological pathologies excluding diabetes mellitus
  • advanced chronic renal failure (GFR \< 35 ml/min)
  • pregnant women
  • impossibility to participate to the rehabilitation protocol or to perform the established controls
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    cardiopathic patients in hypovitaminosis

    Didrogyl 10 ml: 10 drops a day to obtain levels of vitamin D \> 30 ng /ml. Once these values are obtained lower the dose to 4-5 drops a day, with the aim, however, of keeping the plasma values between 30 and 60 ng/ml during 6 months of the study

    Drug: Didrogyl

Interventions

  • DrugDidrogyl

    Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels\> 30 ng / ml are obtained. Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study.

05

What researchers measure

Primary outcomes

  1. Evaluation of improvement of ejection fraction (FE)

    Evaluation of improvement of ejection fraction (FE) or longitudinal strain calculated by speckle tracking at 6 months in cardiopathic patients with vitamin D deficiency who underwent supplementation with calcifediol, during functional recovery after major orthopedic surgery

    Time frame: 6 months

06

Study locations

1 site
  • IRCCS Istituto Ortopedico Galeazzi
    Milan, Italy
07

Registry details

Key details

Study ID
NCT03403933
Lead sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Jan 16, 2017
Primary completion
Sep 23, 2017
Completion
Jul 16, 2018
Last update
May 9, 2023

Study contacts

Maurizio Turiel
principal investigator · IRCCS Istituto Ortopedico Galeazzi

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion